ArticleTransplantation direct2026
Respiratory Syncytial Virus Vaccination Strongly Induces RSVpreF-specific IgG and Neutralizing Activity in Immunocompromised Individuals.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Protein-based respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccines show promising immunogenicity in immunocompromised individuals. We have recently shown that RSV-specific CD4 T-cell responses and IgG antibodies were significantly induced, but data on functional humoral responses as well as associations between cellular and humoral immunological endpoints remain limited. We therefore extended our previous studies and performed a head-to-head assessment of vaccine-specific RSVpreF IgG and neutralizing antibody activity across different immunocompromised populations, including kidney and lung transplant recipients, patients on hemodialysis, and patients with CKD. Methods: Conformation-specific RSVpreF-specific IgG levels and RSV-neutralizing plasma activity were assessed before and 13-18 d after RSV vaccination in 61 patients with chronic kidney disease (CKD), 15 patients receiving hemodialysis, 46 kidney transplant (KTx) recipients, and 31 lung transplant (LuTx) recipients. RSVpreF-specific IgG was measured by ELISA and neutralizing activity using an RSV-pseudovirus assay. Furthermore, comprehensive correlation analyses were carried out to assess associations between vaccine-induced humoral immune parameters and cellular immunity. Results: Vaccination significantly increased RSVpreF-specific IgG ( Conclusions: RSV vaccination induces robust functional humoral immunity in all tested immunocompromised patient groups, but responses are lowest in kidney transplant recipients. Among transplant recipients, responses were reduced within the first year after transplantation and in patients on MMF/MPA, supporting the need for optimized vaccination strategies in these patient groups.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.